Urinary interleukin-9 in youth with type 1 diabetes mellitus.


Journal

Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 18 10 2021
accepted: 20 02 2022
pubmed: 22 4 2022
medline: 3 6 2022
entrez: 21 4 2022
Statut: ppublish

Résumé

Interleukin-9 (IL-9) attenuates podocyte injury in experimental kidney disease, but its role in diabetic nephropathy is unknown. We sought to relate urinary IL-9 levels to the release of podocyte-derived extracellular vesicles (EVs) in youth with type 1 diabetes. We related urinary IL-9 levels to clinical variables and studied interactions between urinary IL-9, vascular endothelial growth factor (VEGF), tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) on urinary albumin/creatinine ratio (ACR) a functional measure of podocyte injury. We performed an analysis of urine samples and clinical data from a cohort of youth with type 1 diabetes (n = 53). Cytokines were measured using a Luminex platform (Eve Technologies), and nanoscale flow cytometry was employed to quantify urinary podocyte-derived EVs. All urinary measures were normalized to urinary creatinine. Mean age was 14.7 ± 1.6 years, and the mean time from diagnosis was 6.7 ± 2.9 years. Mean HbA1c was 70.3 ± 13.9 mmol/mol, mean ACR was 1.3 ± 1.9 mg/mmol, and mean eGFR was 140.3 ± 32.6 ml/min/1.73 m IL-9 is associated with podocyte injury in early type 1 diabetes, and there are complex interactions between urinary IL-9, inflammatory cytokines and ACR.

Identifiants

pubmed: 35445345
doi: 10.1007/s00592-022-01873-4
pii: 10.1007/s00592-022-01873-4
pmc: PMC9156513
doi:

Substances chimiques

Biomarkers 0
Cytokines 0
Glycated Hemoglobin A 0
IL9 protein, human 0
Interleukin-6 0
Interleukin-9 0
Tumor Necrosis Factor-alpha 0
Vascular Endothelial Growth Factor A 0
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

939-947

Subventions

Organisme : CIHR
ID : MOP-343810
Pays : Canada
Organisme : CIHR
ID : MOP-343810
Pays : Canada

Informations de copyright

© 2022. The Author(s).

Références

Goswami R, Kaplan MH (2011) A Brief History of IL-9. J Immunol 186(6):3283–3288
doi: 10.4049/jimmunol.1003049
Chakraborty S, Kubatzky KF, Mitra D (2019) An update on interleukin-9: from its cellular source and signal transduction to its role in immunopathogenesis. Int J Mol Sci 20(9):3
doi: 10.3390/ijms20092113
Ouyang H, Shi Y, Liu Z, Feng S, Li L, Su N et al (2013) Increased Interleukin-9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep 7(3):1031–1037
doi: 10.3892/mmr.2013.1258
Hoppenot D, Malakauskas K, Lavinskiene S, Bajoriuniene I, Kalinauskaite V, Sakalauskas R (2015) Peripheral blood Th9 cells and eosinophil apoptosis in asthma patients. Med 51(1):10–17
Gregersen I, Skjelland M, Holm S, Holven KB, Krogh-Sørensen K, Russell D et al (2013) Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosis. PLoS ONE 8(8):e72769
doi: 10.1371/journal.pone.0072769
Xiong T, Attar M, Gnirck AC, Wunderlich M, Becker M, Rickassel C et al (2020) Interleukin-9 protects from early podocyte injury and progressive glomerulosclerosis in Adriamycin induced nephropathy. Kidney Int 98(3):615–629
doi: 10.1016/j.kint.2020.04.036
Fioretto P, Mauer M (2007) Histopathology of diabetic nephropathy. Semin Nephrol 27(2):195–207
doi: 10.1016/j.semnephrol.2007.01.012
Toyoda M, Najafian B, Kim Y et al (2007) Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 56:2155–2160
doi: 10.2337/db07-0019
Susztak K, Raff AC, Schiffer M, Böttinger EP (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55(1):225–233
doi: 10.2337/diabetes.55.01.06.db05-0894
Shah R, Patel T, Freedman JE (2018) Circulating extracellular vesicles in human disease. N Engl J Med 379(10):958–966
doi: 10.1056/NEJMra1704286
Medeiros T, Myette RL, Almeida JR, Silva AA, Burger D (2020) Extracellular vesicles: cell-derived biomarkers of glomerular and tubular injury. Cell Physiol Biochem 54(1):88–109
doi: 10.33594/000000207
Erdbrügger U, Le TH (2016) Extracellular vesicles in renal diseases: more than novel biomarkers? J Am Soc Nephrol 27(1):12–26
doi: 10.1681/ASN.2015010074
Burger D, Thibodeau JF, Holterman CE, Burns KD, Touyz RM, Kennedy CRJ (2014) Urinary podocyte microparticles identify prealbuminuric diabetic glomerular injury. J Am Soc Nephrol 25(7):1401–1407
doi: 10.1681/ASN.2013070763
Lytvyn Y, Xiao F, Kennedy CRJ, Perkins BA, Reich HN, Scholey JW et al (2017) Assessment of urinary microparticles in normotensive patients with T1D. Diabetologia 60(3):581–584
doi: 10.1007/s00125-016-4190-2
Sullivan KM, Scholey J, Moineddin R, Sochett E, Wicklow B, Elia Y et al (2021) Urinary podocyte-derived microparticles in youth with type 1 and type 2 diabetes. Diabetologia 64(2):469–475. https://doi.org/10.1007/s00125-020-05297-z
doi: 10.1007/s00125-020-05297-z pubmed: 33037887
Sivaskandarajah GA, Jeansson M, Maezawa Y, Eremina V, Baelde HJ, Quaggin SE (2012) Vegfa protects the glomerular microvasculature in diabetes. Diabetes 61(11):2958–2966
doi: 10.2337/DB11-1655
Suzuki D, Miyazaki M, Naka R et al (1995) In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44:1233–1238
doi: 10.2337/diab.44.10.1233
Purohit S, Sharma A, Zhi W, Bai S, Hopkins D, Steed L et al (2018) Proteins of TNF-α and IL6 pathways are elevated in serum of type-1 diabetes patients with microalbuminuria. Front Immunol 31(9):154
doi: 10.3389/fimmu.2018.00154
Har RLH, Reich HN, Scholey JW, Daneman D, Dunger DB, Moineddin R et al (2014) The urinary cytokine/chemokine signature of renal hyperfiltration in adolescents with T1D. PLoS ONE 9(11):e111131
doi: 10.1371/journal.pone.0111131
Cherney DZI, Scholey JW, Daneman D, Dunger DB, Dalton RN, Moineddin R et al (2012) Urinary markers of renal inflammation in adolescents with type1 diabetes mellitus and normoalbuminuria. Diabet Med 29(10):1297–1302
doi: 10.1111/j.1464-5491.2012.03651.x
Diabetes Canada Clinical Practice Guidelines Expert Committee (2018) Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabet 42(Suppl 1):S1–S325
Flynn JT, Falkner BE (2017) New clinical practice guideline for the management of high blood pressure in children and adolescents. Hypertension 70(4):683–686
doi: 10.1161/HYPERTENSIONAHA.117.10050
De Melo EN, Deda L, Har R, Reich HN, Scholey JW, Daneman D et al (2016) The urinary inflammatory profile in gluten free diet-Adherent adolescents with T1D and celiac disease. J Diabet Complications 30(2):295–299
doi: 10.1016/j.jdiacomp.2015.11.020
Vasanthakumar R, Mohan V, Anand G, Deepa M, Babu S, Aravindhan V (2015) Serum IL-9, IL-17, and TGF-β levels in subjects with diabetic kidney disease (CURES-134). Cytokine 72(1):109–112
doi: 10.1016/j.cyto.2014.10.009
The Microalbuminuria Collaborative Study Group (1999) Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. Diabet Med 16(11):918–925
doi: 10.1046/j.1464-5491.1999.00182.x
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
doi: 10.1056/NEJM199309303291401
Dahlquist G, Stattin EL, Rudberg S (2001) Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy: a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol Dial Transpl 16:1382–1386
doi: 10.1093/ndt/16.7.1382
Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ (1999) Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 34(5):809–817. https://doi.org/10.1016/S0272-6386(99)70036-3
doi: 10.1016/S0272-6386(99)70036-3 pubmed: 10561135
Majumder S, Advani A (2017) VEGF and the diabetic kidney: more than too much of a good thing. J Diabet Complicat 31(1):273–279
doi: 10.1016/j.jdiacomp.2016.10.020
Fernández-Real JM, Vendrell J, García I, Ricart W, Valles M (2012) Structural damage in diabetic nephropathy is associated with TNF-α system activity. Acta Diabetol 49(4):301–305
doi: 10.1007/s00592-011-0349-y
Dalla Vestra M, Mussap M, Gallina P et al (2005) Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 16(Suppl 1):S78–S82
doi: 10.1681/ASN.2004110961
Jiang Y, Chen J, Bi E, Zhao Y, Qin T, Wang Y et al (2019) TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways. J Immunother Cancer 7(1):1–12
doi: 10.1186/s40425-018-0494-8
Schütze N, Trojandt S, Kuhn S, Tomm JM, von Bergen M, Simon JC et al (2016) Allergen-Induced IL-6 Regulates IL-9/IL-17A Balance in CD4 + T Cells in Allergic Airway Inflammation. J Immunol 197(7):2653–2664
doi: 10.4049/jimmunol.1501599
Moon JY, Jeong KH, Lee TW, Ihm CG, Lim SJ, Lee SH (2012) Aberrant recruitment and activation of T cells in diabetic nephropathy. Am J Nephrol 35(2):164–174
doi: 10.1159/000334928
Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40(7):1830–1835
doi: 10.1002/eji.201040391
Eller K, Wolf D, Huber JM, Metz M, Mayer G, McKenzie ANJ et al (2011) IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol 186(1):83–91
doi: 10.4049/jimmunol.1001183
Mensah-Brown EPK, Obineche EN, Galadari S, Chandranath E, Shahin A, Ahmed I et al (2005) Streptozotocin-induced diabetic nephropathy in rats: the role of inflammatory cytokines. Cytokine 31(3):180–190
doi: 10.1016/j.cyto.2005.04.006

Auteurs

Julie Semenchuk (J)

Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada. julie.semenchuk@mail.utoronto.ca.

Katie Sullivan (K)

Department of Medicine, Renal and Hypertension Division, University of Pennsylvania, Philadelphia, USA.

Rahim Moineddin (R)

Department of Family and Community Medicine, University of Toronto, Toronto, Canada.

Farid Mahmud (F)

Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada.

Allison Dart (A)

Department of Pediatrics and Child Health, Children's Hospital Research Institute of Manitoba, Diabetes Research Envisioned and Accomplished in Manitoba Research Team, University of Manitoba, Winnipeg, Canada.

Brandy Wicklow (B)

Department of Pediatrics and Child Health, Children's Hospital Research Institute of Manitoba, Diabetes Research Envisioned and Accomplished in Manitoba Research Team, University of Manitoba, Winnipeg, Canada.

Fengxia Xiao (F)

Department of Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.

Thalia Medeiros (T)

Department of Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.

James Scholey (J)

Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
Department of Physiology, University of Toronto, Toronto, Canada.

Dylan Burger (D)

Department of Medicine, Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH